2 hours ago
3
Prosper Junior Bakiny, The Motley Fool
Sat, August 15, 2026 astatine 1:20 PM CDT 5 min read
Eli Lilly (NYSE: LLY) has been posting outstanding fiscal results implicit the past fewer years. The institution owes this occurrence partially to its enactment successful the weight-loss market. Eli Lilly's Zepbound is the person successful this niche and is increasing income rapidly. However, immoderate investors fearfulness that the enactment won't past overmuch longer. As new, competing value nonaccomplishment drugs participate the market, Eli Lilly volition suffer marketplace stock and pricing power, starring to slower income growth, oregon truthful the statement goes. The bully quality is that Eli Lilly is preparing for that possibility, and portion of the company's strategy is to make value nonaccomplishment medicines that cater to astir each benignant of patient. Here's what investors request to know.
Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »
Something for (almost) everyone
Zepbound was Eli Lilly's archetypal value nonaccomplishment cause to gain approval. It's a highly effectual injectable medicine administered erstwhile weekly. But immoderate patients don't similar needles. To cater to them, Eli Lilly developed Foundayo, an oral anti-obesity medicine that was approved successful April. As the institution points out, its strategy has worked: More than 80% of Foundayo prescriptions person been for patients who had ne'er taken GLP-1s before.
In different words, Foundayo helped Eli Lilly grow its marketplace and scope radical it different wouldn't person reached. Retatrutide, Eli Lilly's next-gen medicine, whitethorn bash the same. Although Zepbound is effective, retatrutide seems to beryllium adjacent better, based connected signifier 3 information the institution has revealed. Retatrutide besides showed beardown results successful reducing A1C levels successful patients with diabetes, portion reducing obstructive slumber apnea and genu osteoarthritis pain. Retatrutide won't regenerate Zepbound for everyone.
Rather, it volition propulsion the weight-loss ceiling higher and beryllium an particularly almighty enactment for patients who request substantially much value nonaccomplishment oregon who person obesity-related complications (or both). In fact, adjacent though it isn't approved yet, Eli Lilly has already granted aboriginal entree to retatrutide to immoderate people. Eligible patients indispensable beryllium implicit 18, ineligible for retatrutide objective trials, person refractory obesity, and person astatine slightest 2 superior oregon life-threatening obesity-related conditions. This is simply a marketplace neither Foundayo nor Zepbound tin reach.
Elsewhere, Eli Lilly is processing eloralintide, which, dissimilar its different medicines mentioned truthful far, isn't a GLP-1 drug. Eloralintide mimics the enactment of the amylin hormone, which besides helps modulate satiety. What's the intent of this drug? Traditional GLP-1s sometimes person important gastrointestinal-related broadside effects. But successful a signifier 2 study, eloralintide posted GLP-1-like weight-loss efficacy numbers with improved tolerability.
.png)
English (CA) · 
English (US) · 
Spanish (MX) ·